Sign in Subscribe
Universities and colleges

Breakthrough Vaccine Shows Promise in Treating Cancers with Common Carbohydrate Signature

Strategic Insights

— 1 min read

Researchers at the University of Georgia and the Mayo Clinic in Arizona have made a significant breakthrough in cancer treatment with the development of a vaccine that reduces tumors in a mouse model that mimics 90% of human breast and pancreatic cancer cases, including those resistant to common treatments. This innovative vaccine targets cancers that share a distinct carbohydrate signature, including ovarian and colorectal cancers. The researchers used unique mice that overexpress a protein known as MUC1 on the surface of their cells, a characteristic also found in more than 70% of cancers that kill.

Key Takeaways:

  • The vaccine, developed by researchers from the University of Georgia and the Mayo Clinic in Arizona, dramatically reduces tumors in a mouse model mimicking 90% of human breast and pancreatic cancer cases.
  • The vaccine targets cancers that share a distinct carbohydrate signature, including ovarian and colorectal cancers.
  • The vaccine's unique design consists of three components: an immune system booster, a component triggering the production of T-helper cells, and a carbohydrate-linked peptide molecule directing the immune response to cells bearing MUC1 proteins with truncated carbohydrates.
  • Unlike traditional cancer treatments like Provenge, the vaccine is fully synthetic and can be manufactured in a lab with assembly-line precision.
  • The researchers used unique mice developed by Sandra Gendler, Grohne Professor of Therapeutics for Cancer Research at the Mayo Clinic, which overexpress the protein MUC1 on their cell surfaces.
  • MUC1 is found on more than 70% of cancers that kill, making this vaccine a promising strategy for treating a wide range of cancer types.

Statistics:

  • 90% of human breast and pancreatic cancer cases are mimicked in the mouse model used in the study.
  • More than 70% of cancers that kill are associated with the protein MUC1.
  • The vaccine is designed to targets cancers that share a distinct carbohydrate signature, including ovarian and colorectal cancers.

Sources:

  • Proceedings of the National Academy of Sciences (journal)
  • University of Georgia (research institution)
  • Mayo Clinic in Arizona (research institution)
  • Sandra Gendler (Grohne Professor of Therapeutics for Cancer Research, Mayo Clinic)

Read more